Cargando…
Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril–valsartan
Angiotensin inhibition remains a cornerstone for pharmacologic management of heart failure (HF), despite being associated with decreased hemoglobin (Hb) levels. To investigate the effect of anemia and its treatment on patients with HF treated with sacubitril–valsartan (S/V), we conducted a retrospec...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114364/ https://www.ncbi.nlm.nih.gov/pubmed/35581275 http://dx.doi.org/10.1038/s41598-022-11886-2 |